Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 16 August 2022, 09:00 HKT/SGT
Share:
    

Source: Essex Bio-Technology Limited
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022"

HONG KONG, Aug 16, 2022 - (ACN Newswire) - Essex Bio-Technology Ltd ("EssexBio" or the "Group", Stock Code: 1061.HK) is pleased and honoured to announce that it is included in "Forbes Asia's 200 Best Under A Billion 2022" - for the Group's outstanding long-term sustainable development across a variety of metrics.

(Source: forbes.com)

Only 200 companies were selected out of 20,000 publicly traded companies (with annual sales of between $10 million and $1 billion) in the Asia-Pacific region. The 200 companies were carefully picked based on Forbes' List Methodology ^ of quantitative criteria and qualitative screens.

EssexBio would like to extend its gratitude to all stakeholders for their contributions. For sustainable long-term growth and enhancing shareholder value, EssexBio will continue to strive for excellence by embracing innovation to develop first-in-class and best-in-class products - providing solutions for Tomorrow's healthcare problems, Today.

About Essex (1061.HK)
Essex Bio-Technology Limited is a biopharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic b-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and Shilishun (Iodized Lecithin Capsules) etc. The products of the Company are principally prescribed for the treatment of wound healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 10,500 hospitals and managed directly by its 43 regional sales offices in China. Leveraging on its in-house R&D platform in growth factors and antibodies, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.

^Forbes' List Methodology (Source: forbes.com)
This list is meant to identify companies with long-term sustainable performance across a variety of metrics. From a universe of 20,000 publicly traded companies in the Asia-Pacific region with annual sales above $10 million and below $1 billion, these 200 companies were selected. The companies on this list, which is unranked, were selected based on a composite score that incorporated their overall track record in measures such as debt, sales and earnings-per-share growth over both the most recent fiscal one- and three-year periods, and the strongest one- and five-year average returns on equity. Aside from quantitative criteria, qualitative screens were used as well, such as excluding companies with serious governance issues, questionable accounting, environmental concerns, management issues, or legal troubles. State-controlled and subsidiaries of larger companies were also excluded. The criteria also ensured a geographic diversity of companies from across the region. The list uses full-year annual results, based on the latest publicly available figures as of July 11, 2022.


Topic: Press release summary
Source: Essex Bio-Technology Limited

Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Essex Bio-Technology Limited
Mar 18, 2024 21:30 HKT/SGT
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%
Aug 16, 2023 19:06 HKT/SGT
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
July 26, 2023 18:58 HKT/SGT
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
Apr 14, 2023 17:18 HKT/SGT
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
Apr 11, 2023 12:58 HKT/SGT
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China
Mar 8, 2023 20:28 HKT/SGT
Essex Bio-Technology Announces 2022 Annual Financial Results
Feb 22, 2023 18:48 HKT/SGT
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
Feb 10, 2023 21:06 HKT/SGT
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
Oct 13, 2022 22:40 HKT/SGT
Essex Biotechnology Secures Exclusive Rights and Interests in SkQ1 for Ophthalmology from Mitotech
Mar 22, 2022 20:12 HKT/SGT
Essex Bio-Technology Announces 2021 Financial Results
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: